X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Lead Product(s): Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2023
Details:
Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Lead Product(s): Abiraterone Decanoate,Prednisone,Dexamethasone
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2023
Details:
PRL-02 (abiraterone decanoate) is routed through the lymph to target tissues where it releases the precise level of abiraterone needed to block CYP17 lyase for 12 weeks, thereby reducing interim tumor breakthrough risk.
Lead Product(s): Abiraterone Decanoate,Prednisone,Dexamethasone
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
PRL-02 (abiraterone decanoate), is long-acting, selective CYP17 lyase inhibitor that has been designed for optimal uptake through lymphatic system so that a precise level of abiraterone can be released to continuously block CYP17 lyase over a three-month period.
Lead Product(s): Abiraterone Decanoate
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.
Lead Product(s): Capsaicin
Therapeutic Area: Musculoskeletal Product Name: CGS-200-5
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aosaikang Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 07, 2022
Details:
Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Lead Product(s): Abiraterone Decanoate
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 23, 2021
Details:
The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, protects certain novel prodrugs.
Lead Product(s): Abiraterone Decanoate
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
